{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:34:03Z","timestamp":1783499643261,"version":"3.55.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002733"],"award-info":[{"award-number":["UL1TR002733"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Lower mortality has been observed with combination therapy compared to monotherapy for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia; however, there is a lack of evidence for continued combination therapy over de-escalation to monotherapy following bacteremia clearance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a single-center, retrospective study evaluating patients with MRSA bacteremia hospitalized from November 1, 2011, through July 31, 2019. Patients who received three to ten days of combination therapy followed by de-escalation to monotherapy were directly compared to patients retained on combination therapy. The primary composite outcome included inpatient infection-related mortality, 60-day readmission, and 60-day bacteremia recurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 286 patients with MRSA bacteremia were identified, with 146 patients omitted based on exclusion criteria. The study population included 66 in the combination therapy group and 74 in the monotherapy group. Study population was 51% female (n = 71) and 78% white (n = 109) with median age of 46 years (IQR 34.5\u201361). No significant difference was observed in the primary composite outcome (21% combination therapy group vs 24% monotherapy group; P =.66), with retained observations after controlling for confounders. Within this outcome, there was no significant difference in 60-day readmission (20% combination therapy group vs 18% monotherapy group; P =.75), bacteremia recurrence (3% combination therapy group vs 7% monotherapy group; P =.45), or inpatient infection-related mortality (2% combination therapy group vs 5% monotherapy group; P = 1.00).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>No difference was found in the composite outcome of 60-day bacteremia recurrence, readmission, or inpatient infection-related mortality for patients with MRSA bacteremia retained on combination therapy versus those de-escalated to monotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofab327","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T13:49:45Z","timestamp":1624369785000},"source":"Crossref","is-referenced-by-count":25,"title":["Clinical Outcomes With Definitive Treatment of Methicillin-Resistant <i>Staphylococcus aureus<\/i> Bacteremia With Retained Daptomycin and Ceftaroline Combination Therapy vs De-escalation to Monotherapy With Vancomycin, Daptomycin, or Ceftaroline"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8194-7006","authenticated-orcid":false,"given":"Courtney N","family":"Nichols","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3539-4850","authenticated-orcid":false,"given":"Lynn C","family":"Wardlow","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1012-5512","authenticated-orcid":false,"given":"Kelci E","family":"Coe","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2017-2726","authenticated-orcid":false,"given":"Mohammad Mahdee E","family":"Sobhanie","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"2021072911415162100_CIT0001","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jac\/dkv368","article-title":"When sepsis persists: a review of MRSA bacteraemia salvage therapy","volume":"71","author":"Kullar","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021072911415162100_CIT0002","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2021072911415162100_CIT0003","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1086\/598189","article-title":"Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies","volume":"48","author":"Naber","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2021072911415162100_CIT0004","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/archinte.167.17.1861","article-title":"Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes","volume":"167","author":"Hawkins","year":"2007","journal-title":"Arch Intern Med"},{"key":"2021072911415162100_CIT0005","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1001\/archinte.163.17.2066","article-title":"Clinical identifiers of complicated Staphylococcus aureus bacteremia","volume":"163","author":"Fowler","year":"2003","journal-title":"Arch Intern Med"},{"key":"2021072911415162100_CIT0006","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2021072911415162100_CIT0007","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and \u00df-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021072911415162100_CIT0008","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"2021072911415162100_CIT0009","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.clinthera.2014.09.005","article-title":"Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia","volume":"36","author":"Dhand","year":"2014","journal-title":"Clin Ther"},{"key":"2021072911415162100_CIT0010","first-page":"1","article-title":"Daptomycin plus \u00df-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study","volume":"20","author":"Jorgensen","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021072911415162100_CIT0011","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1128\/AAC.01204-13","article-title":"\u03b2-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone","volume":"58","author":"Dilworth","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021072911415162100_CIT0012","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments","volume":"7","author":"McCreary","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2021072911415162100_CIT0013","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/dku378","article-title":"The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA","volume":"70","author":"Barber","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2021072911415162100_CIT0014","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021072911415162100_CIT0015","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1128\/AAC.01525-12","article-title":"\u03b2-lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives","volume":"56","author":"Mehta","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021072911415162100_CIT0016","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1128\/AAC.00797-12","article-title":"Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity","volume":"56","author":"Rose","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021072911415162100_CIT0017","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2014.07.024","article-title":"Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations","volume":"44","author":"Paladino","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2021072911415162100_CIT0018","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021072911415162100_CIT0019","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02015-16","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"61","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021072911415162100_CIT0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/AAC.01586-12","article-title":"Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021072911415162100_CIT0021","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2021072911415162100_CIT0022","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2021072911415162100_CIT0023","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40121-020-00292-8","article-title":"Monotherapy with vancomycin or daptomycin versus combination therapy with \u03b2-lactams in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective cohort analysis","volume":"9","author":"Alosaimy","year":"2020","journal-title":"Infect Dis Ther"},{"key":"2021072911415162100_CIT0024","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40121-019-00277-2","article-title":"Comparing the outcomes of ceftaroline plus vancomycin or daptomycin combination therapy versus monotherapy in adults with complicated and prolonged methicillin-resistant Staphylococcus aureus bacteremia initially treated with supplemental ceftaroline","volume":"9","author":"Ahmad","year":"2020","journal-title":"Infect Dis Ther"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofab327\/38756996\/ofab327.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/7\/ofab327\/39427803\/ofab327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/7\/ofab327\/39427803\/ofab327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T11:50:49Z","timestamp":1627559449000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofab327\/6307721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofab327","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,6,22]]},"article-number":"ofab327"}}